NovaBay Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
NovaBay Pharmaceuticals's earnings have been declining at an average annual rate of -15.8%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 13.5% per year.
Key information
-15.8%
Earnings growth rate
30.8%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 13.5% |
Return on equity | n/a |
Net Margin | -120.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How NovaBay Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 14 | -17 | 13 | 0 |
31 Mar 24 | 15 | -19 | 13 | 0 |
31 Dec 23 | 15 | -17 | 13 | 0 |
30 Sep 23 | 13 | -15 | 13 | 0 |
30 Jun 23 | 13 | -19 | 13 | 0 |
31 Mar 23 | 13 | -17 | 14 | 0 |
31 Dec 22 | 14 | -16 | 15 | 0 |
30 Sep 22 | 14 | -9 | 16 | 0 |
30 Jun 22 | 13 | -5 | 17 | 0 |
31 Mar 22 | 12 | -5 | 17 | 0 |
31 Dec 21 | 10 | -7 | 15 | 0 |
30 Sep 21 | 9 | -7 | 13 | 0 |
30 Jun 21 | 8 | -8 | 13 | 0 |
31 Mar 21 | 10 | -11 | 12 | 0 |
31 Dec 20 | 10 | -11 | 12 | 0 |
30 Sep 20 | 10 | -13 | 13 | 0 |
30 Jun 20 | 9 | -10 | 12 | 0 |
31 Mar 20 | 7 | -8 | 12 | 0 |
31 Dec 19 | 7 | -10 | 14 | 0 |
30 Sep 19 | 8 | -8 | 15 | 0 |
30 Jun 19 | 10 | -10 | 17 | 0 |
31 Mar 19 | 11 | -9 | 19 | 0 |
31 Dec 18 | 13 | -7 | 19 | 0 |
30 Sep 18 | 15 | -4 | 19 | 0 |
30 Jun 18 | 16 | -5 | 20 | 0 |
31 Mar 18 | 17 | -6 | 21 | 0 |
31 Dec 17 | 18 | -7 | 22 | 0 |
30 Sep 17 | 16 | -10 | 23 | 0 |
30 Jun 17 | 15 | -11 | 22 | 0 |
31 Mar 17 | 14 | -12 | 21 | 1 |
31 Dec 16 | 12 | -13 | 19 | 1 |
30 Sep 16 | 9 | -16 | 20 | 2 |
30 Jun 16 | 7 | -17 | 20 | 4 |
31 Mar 16 | 6 | -19 | 20 | 5 |
31 Dec 15 | 4 | -19 | 19 | 6 |
30 Sep 15 | 3 | -19 | 15 | 7 |
30 Jun 15 | 2 | -18 | 12 | 8 |
31 Mar 15 | 1 | -16 | 10 | 11 |
31 Dec 14 | 1 | -15 | 8 | 9 |
30 Sep 14 | 1 | -15 | 7 | 20 |
30 Jun 14 | 2 | -14 | 6 | 17 |
31 Mar 14 | 3 | -16 | 6 | 12 |
31 Dec 13 | 3 | -16 | 6 | 12 |
30 Sep 13 | 4 | -14 | 7 | 0 |
Quality Earnings: B9P0 is currently unprofitable.
Growing Profit Margin: B9P0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: B9P0 is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.
Accelerating Growth: Unable to compare B9P0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: B9P0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: B9P0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.